|Bid||80.89 x 100|
|Ask||83.32 x 100|
|Day's Range||81.39 - 82.42|
|52 Week Range||64.18 - 86.72|
|PE Ratio (TTM)||35.49|
|Dividend & Yield||2.08 (2.54%)|
|1y Target Est||N/A|
Eli Lilly • LLY-NYSE Long-Term Buy • Price $82.17 on Sept. 12 by Hilliard Lyons At the European Society for Medical Oncology Annual Congress, Lilly presented strong data from a key trial on its cancer drug Abemaciclib. As a reminder to investors, while cross-trial comparisons are difficult to make, the presentation provided physicians and investors the best opportunity to compare Abemaciclib to the other CDK4/6 inhibitors, and we think it can take some market share from competitors in this niche.
The charts don't look positive for drug company Eli Lilly.
Theravance and Exelixis tick off most of the acquisition boxes for Big Pharma, an analyst said Friday.